Project Grant K08AI197864
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$198K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award of $858,186 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to decipher the mechanisms leading to immune-related myocarditis, a fatal adverse event associated with immune checkpoint inhibitor (ICI) cancer therapies. The research aims to identify novel...
The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The $117,804 award to The Leland Stanford Junior University (Stanford University) aims to investigate the role of macrophages and T-cell recruitment in immune checkpoint inhibitor-induced myocarditis, a life-threatening side effect of cancer immunotherapies. Specifically,...
The Department of the Army Medical Command awarded a $695,089 Project Grant to the Dana-Farber Cancer Institute, Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 1, 2022 to May 31, 2025 to develop noninvasive diagnosis of immune checkpoint inhibitor-associated myocarditis. The Military Medical Research and Development program supports biomedical research that transforms military and public health care through innovative...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,074,434.37 Project Grant to the Massachusetts General Hospital under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 17, 2021 with a completion date of July 12, 2021. The grant funding supports research to develop protocols to induce tolerance in non-human primate heart allograft recipients without chronic immunosuppression. The awardee will test approaches to either...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) at the National Institutes of Health provides $167,864 to The Leland Stanford Junior University to investigate risk stratification and outcomes across the spectrum of cardiotoxicity from immune checkpoint inhibitor cancer therapies. The study aims to: 1) retrospectively examine cardiac and oncologic outcomes associated with immune checkpoint inhibitor cardiotoxicity based on...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $112,822 to The Washington University in St. Louis to investigate the role of dendritic cell lysosome activity in immune checkpoint inhibitor (ICI)-associated myocarditis. The research aims to: 1) characterize differences in lysosomal activity between wild-type dendritic cells and dendritic cells deficient in the PD-1 immune checkpoint receptor, and establish a...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of a novel monocyte transcriptional state, termed "monocyte substate 1" (MS1), in the immunopathogenesis and patient heterogeneity of sepsis. The 5-year project will apply single-cell RNA...
This federal Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research to investigate the effect of aging on CDC1 function and CD8 T cell immunity in tumors. The $176,040 award to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will fund a study to understand how age-related declines in conventional type 1 dendritic cells (CDC1s) impact the effectiveness of CD8+ T cell...